Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
Milestone Comes During National Thyroid Awareness Month
“This is a significant milestone and we’re proud to be leading in a new
era of genomic medicine in which our Afirma classifier is giving
physicians and patients better diagnostic answers,” said
Data suggest that the Afirma Genomic Sequencing Classifier (GSC) can
save nearly 70 percent of patients with benign thyroid nodules from
unnecessary surgery by identifying their nodules as benign following
indeterminate results on their fine needle aspiration (FNA) biopsies.
The enhanced Afirma GSC, which identifies 30 percent more benign cases
than the original Afirma test, was introduced in
“Thyroid cancer diagnosis is a poster child for overtreatment in
medicine,” said Dr.
All patients who undergo full removal of the thyroid (thyroidectomy) and nearly one in five patients who undergo a partial thyroidectomy experience a loss of thyroid function (hypothyroidism), which requires lifelong daily thyroid hormone replacement medication. Patients with hypothyroidism can develop weight gain, fatigue, sleepiness and other symptoms – conditions that can be difficult to regulate even with medication.
Each year in
About Veracyte
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that the use of the Envisia classifier to enable diagnosis of idiopathic pulmonary fibrosis, without the need for invasive, risky and costly surgical procedure; Envisia's ability to further give physicians confidence in using our test in lieu of surgery; and Envisia's ability to significantly improve patient care and reduce healthcare costs. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: benefits of our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180125006102/en/
Source:
for Veracyte, Inc.
Media:
Tracy Morris,
650-380-4413
tracy.morris@veracyte.com
or
Investors:
Keith
Kennedy, 650-243-6357
Chief Financial Officer
keith@veracyte.com